Modality
siRNA
MOA
JAK1/2i
Target
SGLT2
Pathway
mTOR
IgANMeso
Development Pipeline
Preclinical
~Sep 2016
→ ~Dec 2017
Phase 1
~Mar 2018
→ ~Jun 2019
Phase 2
Sep 2019
→ Sep 2027
Phase 2Current
NCT08142378
2,924 pts·Meso
2019-09→2027-09·Completed
2,924 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-09-281.5y awayPh2 Data· Meso
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2
Complet…
Catalysts
Ph2 Data
2027-09-28 · 1.5y away
Meso
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08142378 | Phase 2 | Meso | Completed | 2924 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 |